Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured

CompletedOBSERVATIONAL
Enrollment

164

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

January 16, 2021

Study Completion Date

January 16, 2021

Conditions
Unfractionated Heparin Treatment
Interventions
BIOLOGICAL

measurement of anti-Xa activities

"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."

Trial Locations (8)

21033

CHU de Dijon, Dijon

33604

CHU Bordeaux, Bordeaux

35000

Rennes University Hospital, Rennes

54500

CHU de Nancy, Vandœuvre-lès-Nancy

59037

CHU de Lille, Lille

75010

APHP, CHU Lariboisière, Paris

75743

APHP, HOPITAL Necker enfants malades, Paris

78150

CH de Versailles, Le Chesnay

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT04700670 - Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured | Biotech Hunter | Biotech Hunter